545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)

Giovanni Grignani; Piotr Rutkowski; Celeste Lebbe; Natalie Prinzi; Jean-jaques Grob; Enrica Teresa Tanda; Michele Guida; Melissa Burgess; Jennifer Pulini; Sadhna Shankar; Chuan Tian; Shailender Bhatia

doi:10.1136/jitc-2021-SITC2021.545

Article info

PDF

Regular and Young Investigator Award Abstracts

Clinical Trials In Progress

545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)

Free

Authors

Giovanni Grignani Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy PubMed articles Google scholar articles
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland PubMed articles Google scholar articles
Celeste Lebbe Université de Paris, Department of Dermatology and CIC, AP-HP Hôpital Saint-Louis, Paris, France PubMed articles Google scholar articles
Natalie Prinzi Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy PubMed articles Google scholar articles
Jean-jaques Grob Aix-Marseille University, AP-HM Timone, Marseille, France PubMed articles Google scholar articles
Enrica Teresa Tanda IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genoa, Italy PubMed articles Google scholar articles
Michele Guida Unit Melanoma and Rare Tumors, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy PubMed articles Google scholar articles
Melissa Burgess UPMC Cancer Center, Pittsburgh, PA, USA PubMed articles Google scholar articles
Jennifer Pulini Incyte Corporation, Ambler, USA PubMed articles Google scholar articles
Sadhna Shankar Incyte Corporation, Ambler, USA PubMed articles Google scholar articles
Chuan Tian Incyte Corporation, Ambler, USA PubMed articles Google scholar articles
Shailender Bhatia University of Washington, Seattle, WA, USA PubMed articles Google scholar articles

Citation

Grignani G, Rutkowski P, Lebbe C, et al

545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.545

Publication history

First published November 10, 2021.

Online issue publication

March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password